Teva Pharmaceutical Industries Limited (TEVJF)
| Previous close | 10.25 |
| Open | 10.25 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 10.25 - 10.25 |
| 52-week range | 7.03 - 12.73 |
| Volume | |
| Avg. volume | 63 |
| Market cap | 11.856B |
| Beta (5Y monthly) | 1.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Nov 2017 |
| 1y target est | N/A |
Motley Fool3 No-Brainer Stocks to Buy With $20 Right Now
For the past three years, Wall Street has been testing the conviction of investors. Considering how much debt the legacy telecom companies are lugging around, they can ill afford unexpected financial liabilities.
Business WireTeva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
TEL AVIV, Israel, September 06, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 11, 2023. The presentation will begin at 8:40 A.M. Eastern Time.
Business WireTeva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
TEL AVIV, Israel & PARSIPPANY, N.J., September 06, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 16 data presentations across its neuroscience portfolio happening at Psych Congress on September 6-10 in Nashville, TN. Abstracts include data for AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY. Once-daily AUSTEDO XR, a new formulation of twice-daily AUSTEDO was approved by the U.S. Food and Drug administration (F
